Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTT | P42858 | 2/20 | 0.55 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 2/20 | 0.55 |
| ▸ | NPC1 | O15118 | 1/20 | 0.50 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.49 |
| ▸ | LMNA | P02545 | 2/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.39 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30887389 | 0.85 | HTT (0.58) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL16939046 | 0.84 | HTT (0.60) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL29076824 | 0.84 | HTT (0.53) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL30887393 | 0.83 | HTT (0.71) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL8663227 | 0.82 | HTT (0.55) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL17128942 | 0.82 | SMN1; SMN2 (0.55) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL10561186 | 0.82 | HTT (0.69) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| Hydrochloric Acid SCHEMBL8662185 | 0.81 | HTT (0.54) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL30983025 | 0.80 | HTT (0.53) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A | |
| SCHEMBL9700018 | 0.80 | HTT (0.53) | HTTSMN1; SMN2MEN1ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050288187-A1 | Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases | ROCKEFELLER UNIVERSITY, THE | 2005-12-29 | — | — | US | disclosed |
| US-6080766-A | ADMINISTERING TO A PATIENT AN EFFECTIVE AMOUNT OF A HYDROXYPYRROLIDONE COMPOUND TO SUPPRESS THE FORMATION OF COLLAGEN-LIKE SUBSTANCES OR BIOSYNTHESIS OF PROCOLLAGEN | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-06-27 | — | — | US | disclosed |
| US-6046219-A | ADMINISTERING TO THE PATIENT FOR TREATING THE CONDITIONS MEDIATED BY COLLAGEN FORMATION TOGETHER WITH CELL PROLIFERATION A HYDROXYPYRIDINE DERIVATIVE | CORNELL RESEARCH FOUNDATION, INC. (US) | 2000-04-04 | — | — | US | disclosed |
| US-5965585-A | SUPPRESSING FORMATION OF COLLAGEN AND COLLAGEN-LIKE SUBSTANCES OR BIOSYNTHESIS OF PROCOLLAGEN IN LIVING SYSTEMS BY ADMINISTERING A HYDROXYPYRIDONE COMPOUND ENZYME INHIBITOR OF PROTEIN HYDROXYLASE; ANTISCARRING AGENTS | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5965586-A | Method for the treatment of fibroproliferative disorders by application of inhibitors of protein hydroxylation | CORNELL RESEARCH FOUNDATION, INC. (US) | 1999-10-12 | — | — | US | disclosed |
| US-5849587-A | Method of inhibiting viral replication in eukaryotic cells and of inducing apoptosis of virally-infected cells | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-12-15 | — | — | US | disclosed |
| US-5789426-A | SUPPRESSION FORMATION OF COLLAGEN | CORNELL RESEARCH FOUNDATION, INC. (US) | 1998-08-04 | — | — | US | disclosed |
| US-4908371-A | Pharmaceuticals | CIBA-GEIGY CORPORATION (US) | 1990-03-13 | — | — | US | disclosed |
| EP-0316279-A2 | Ester derivatives of azacyclic hydroxycompounds | CIBA-GEIGY AG (CH) | 1989-05-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050288187-A1 | Inhibitor development for 4-hydroxyphenylpyruvate dioxygenase, employing tyrosinemia 1 as a model for human diseases mediated by 2-oxoacid utilizing dioxygenases | HPD, TH, PDXK | HTT 1095/4885SMN1; SMN2 3995/4885MEN1 3574/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.